WS #9249
No genuinely new material developments in the last 30 minutes. The Iran-Israel escalation narrative remains dominant with no counter-signals or de-escalation. No new data points on Pfizer or Boeing beyond what was previously reported.
Key developments
- Iran launches ballistic missiles and drones at Israel in first direct attack since April ceasefire
- Pfizer VESPER-1 trial shows 16% weight loss at 32 weeks on weekly berobenatide
- Boeing clears key 777X certification hurdle as FAA approves next flight tests
- Amazon's $37B debt raise signals caution amid macro headwinds